Progenics develops innovative medicines and other technologies to target and treat cancer. Progenicsâ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA, PSMA TTC and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLâ˘), and 3) imaging analysis technology. Progenics has two commercial products, RELISTORÂŽ (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy. Source
No articles found.
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January...
Headquartered in Franklin, Tennessee, Acadia He...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TSX: FRX) is a specialty pharmaceutic...
Fennec Pharmaceuticals, Inc., (NASDAQ: FENC; TS...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Join the National Investor Network and get the latest information with your interests in mind.